Amgen

Amgen(AMGN)

THOUSAND OAKS, CA
Biotechnology3 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Biologics

Amgen is a life sciences company focused on Small Molecules, Biologics.

OncologyCardiovascularBone HealthImmunologyNeuroscience
Funding Stage
PUBLIC
Employees
27,000
Open Jobs
1405

Products & Portfolio (33)

8 discontinued products not shown

ACTIMMUNE
interferon gamma-1b
LOE Approaching
SINGLE-USE · VIAL
interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind to the alpha/ beta receptor. Interferon gamma binds to a different cell surface receptor and is classified as Type 2 interferon. Specific effects of interferon gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), activation of natural killer (NK) cells, and the expression of Fc receptors and major histocompatibility antigens. CGD is an inherited disorder of leukocyte function caused by defects in the enzyme complex responsible for phagocyte superoxide generation. ACTIMMUNE does not increase phagocyte superoxide production even in treatment responders. In SMO (an inherited disorder characterized by an osteoclast defect, leading to bone overgrowth, and by deficient phagocyte oxidative metabolism), a treatment-related enhancement of superoxide production by phagocytes was observed. ACTIMMUNE was found to enhance osteoclast function in vivo. In both disorders, the exact mechanism(s) by which ACTIMMUNE has a treatment effect has not been established. Changes in superoxide levels during ACTIMMUNE therapy do not predict efficacy and should not be used to assess patient response to therapy.
1999
30
AIMOVIG
erenumab-aooe
Peak
mAbINJECTION · INJECTABLE
Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
migraine
2018
30
AMJEVITA
adalimumab-atto
Peak
mAbINJECTION · INJECTABLE
Tumor Necrosis Factor Receptor Blocking Activity
2016
30
ARANESP
darbepoetin alfa
LOE Approaching
SUBCUTANEOUS · VIAL
erythropoietin.
anemia due to: Chronic Kidney Disease (CKD) in patients on dialysisanemia due to chronic kidney disease (CKD)including patients on dialysis+5 more
2001
30
AVSOLA
infliximab-axxq
Peak
mAbINJECTION · INJECTABLE
Tumor Necrosis Factor Receptor Blocking Activity
Crohn's DiseaseUlcerative ColitisRheumatoid Arthritis+1 more
2019
30
BKEMV
eculizumab-aeeb
Growth
mAbINJECTION · INJECTABLE
Complement Inhibitors
generalized myasthenia gravis (gMG) in adult patientshemolysis
2024
30
BLINCYTO
blinatumomab
Peak
BsAbINJECTION · INJECTABLE
CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. Blinatumomab mediates the formation of a synapse between the T-cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, which result in redirected lysis of CD19+ cells.
older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in firstsecond complete remission with minimal residual disease (MRD) greater thanequal to 0+6 more
2014
30
CORLANOR
ivabradine
LOE Approaching
ORAL · SOLUTION
hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology ( )] . Corlanor can also inhibit the retinal current I h . I h is involved in curtailing retinal responses to bright light stimuli. Under triggering circumstances (e.g., rapid changes in luminosity), partial inhibition of I h by Corlanor may underlie the luminous phenomena experienced by patients. Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field [see A dverse R eactions ( )] .
stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 monthsolderhospitalization for worsening heart failure in adult patients with stable+4 more
2019
25
EPOGEN/PROCRIT
erythropoietin
LOE Approaching
SINGLE-USE · VIAL
erythropoietin.
anemia due to chronic kidney disease (CKD)including patients on dialysisnot on dialysis to decrease the need for red blood cell (RBC) transfusion+9 more
1989
30
EVENITY
romosozumab-aqqg
Peak
mAbINJECTION · INJECTABLE
sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. Animal studies showed that romosozumab-aqqg stimulates new bone formation on trabecular and cortical bone surfaces by stimulating osteoblastic activity resulting in increases in trabecular and cortical bone mass and improvements in bone structure and strength [see and ] .
osteoporosis in postmenopausal women at high risk for fracturedefinedmultiple risk factors for fracture+1 more
2019
30
IMDELLTRA
tarlatamab-dlle
Growth
BsAbINJECTION · INJECTABLE
Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC.
after platinum - based chemotherapylung cancer
2024
30
KANJINTI
trastuzumab-anns
Peak
mAbSINGLE-DOSE · VIAL
HER2/Neu/cerbB2 Antagonists
2019
30
View all 33 products

Pipeline & Clinical Trials

N/A
Clinical Trials (2)
NCT01652833European Physician Survey of EGFR Inhibitor Prescribing Patterns
N/A
NCT01998607Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
N/A
Peds Metabolic Syndrome in Psoriasis
Psoriasis
N/A
Clinical Trials (1)
NCT00930592Peds Metabolic Syndrome in Psoriasis
N/A
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Osteoporosis, Age-Related
N/A
Clinical Trials (1)
NCT02732210Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
N/A
TAP® Micro Select Device
Obesity
N/A
Clinical Trials (1)
NCT06761703A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
N/A
N/A
Clinical Trials (5)
NCT00094341Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
Phase 4
NCT00127842REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
Phase 4
NCT02346877Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis
Phase 4

+2 more

ITP Registry and Accompanying Biospecimen Collection
Immune Thrombocytopenia
N/A
AMG 701
Various
N/A
Clinical Trials (3)
NCT04998747A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1
NCT03287908A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1
NCT05256446AMG 701 Expanded Access Program
N/A
N/A
Clinical Trials (1)
NCT02297529Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
N/A
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Familial Hypercholesterolemia
N/A
Clinical Trials (1)
NCT02009345Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
N/A
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
Acute Lymphoblastic Leukemia
N/A
Clinical Trials (1)
NCT02010931Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
N/A
Etanercept
Pregnancy
N/A
Clinical Trials (1)
NCT00116272Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
N/A
N/A
Clinical Trials (1)
NCT00148369A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
N/A
N/A
Clinical Trials (5)
NCT00115206Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
Phase 4
NCT00125723FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
Phase 4
NCT00117910Treatment for Elderly Patients With High Risk Breast Cancer
Phase 3

+2 more

Apremilast
Psoriasis
N/A
Clinical Trials (1)
NCT03097003A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium
N/A
Control group
Osteoporosis
N/A
Clinical Trials (2)
NCT00986895A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
Phase 1
NCT00512499Strategies to Treat Osteoporosis Following a Fragility Fracture
N/A
N/A
Clinical Trials (1)
NCT02970747Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
N/A
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Renal Cell Carcinoma
N/A
Clinical Trials (1)
NCT00953446Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma
N/A
Not applicable- observational study
Birth Defect
N/A
Clinical Trials (1)
NCT02090088Nplate® Pregnancy Exposure Registry
N/A
N/A
Clinical Trials (1)
NCT07143513Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
N/A
Chart Review of Repatha® in Subjects With Hyperlipidaemia
Hypercholesterolaemia
N/A
Clinical Trials (1)
NCT02770131Chart Review of Repatha® in Subjects With Hyperlipidaemia
N/A
N/A
Clinical Trials (2)
NCT00117091Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)
Phase 3
NCT00116714Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy
N/A
Early Intervention
Cardiovascular Diseases
N/A
Clinical Trials (1)
NCT05325034Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
N/A
No Intervention for Observational Study
Idiopathic Thrombocytopenic Purpura
N/A
Clinical Trials (1)
NCT00861224Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology
N/A
Romiplostim
Hematology
N/A
Clinical Trials (1)
NCT00472290Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
N/A
N/A
Clinical Trials (1)
NCT01692912Psoriatic Arthritis Treat to Target vs. Usual Care
N/A
Spanish Registry of Systemic Treatments in Psoriasis
Psoriasis
N/A
OFF in experimental arm
Pancreatic Cancer
N/A
Clinical Trials (1)
NCT00786058A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
N/A
N/A
Clinical Trials (1)
NCT03043950Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)
N/A
therascreen® KRAS RGQ PCR Kit
Non Small Cell Lung Cancer
N/A
Clinical Trials (3)
NCT05348187Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
N/A
NCT05360225Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit
N/A
NCT05347745Therascreen® KRAS RGQ PCR Kit
N/A
WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise
Heart Failure
N/A
Clinical Trials (1)
NCT06576050WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise
N/A
N/A
Clinical Trials (1)
NCT05495620Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
N/A
nonmyeloablative stem cell transplant
Metastatic Solid Tumor
N/A
Clinical Trials (1)
NCT00997529Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors
N/A
therascreen® KRAS RGQ PCR Kit
Non-small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT05347797Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit
N/A
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvM
ASCVD
N/A
Clinical Trials (1)
NCT04197453The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
N/A
Apremilast
Psoriasis
N/A
Clinical Trials (1)
NCT03757013A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
N/A
On-body injector
Non Hodgkin Lymphoma
N/A
Clinical Trials (1)
NCT03619993Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
N/A
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
Nsclc
N/A
Clinical Trials (1)
NCT05273047RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
N/A
N/A
Post-Marketing Surveillance Study of OTEZLA
Psoriasis
N/A
Clinical Trials (1)
NCT03284879Post-Marketing Surveillance Study of OTEZLA
N/A
cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
Breast Cancer
N/A
Clinical Trials (1)
NCT00615901Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
N/A
Darbepoetin alfa
Cardiomyopathy
N/A
Clinical Trials (1)
NCT00883415Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
N/A
Interferon gamma-1b
HIV Infections
N/A
Clinical Trials (2)
NCT06529731Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2
NCT00002433The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
N/A
N/A
Clinical Trials (1)
NCT00928408PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
N/A
Observation
Multiple Myeloma
N/A
Clinical Trials (5)
NCT02322736Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
N/A
NCT02303522Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)
N/A
NCT04128475Observational Study of Cardiovascular Disease.
N/A

+2 more

First Report, Five Years Experience of the Acute Leukemia Work Group
Acute Leukemia (Category)
N/A
Clinical Trials (1)
NCT02990104First Report, Five Years Experience of the Acute Leukemia Work Group
N/A
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Lymphoma
N/A
Clinical Trials (1)
NCT00210249Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
N/A
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chem
Breast Cancer
N/A
Clinical Trials (1)
NCT00883181A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
N/A
Integrated Osteoporosis Care
Postmenopausal Osteoporosis
N/A
Clinical Trials (1)
NCT03970902Quality of Life in Postmenopausal Women With Osteoporosis
N/A
N/A
Clinical Trials (2)
NCT03861533GOAL International QuERI - Protocol CHRC 2019 GOAL INTERNATIONAL
N/A
NCT02537535Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada
N/A
Lp(a) and Aortic Valve Calcification
Heterozygous Familial Hypercholesterolemia
N/A
Clinical Trials (1)
NCT02976818Lp(a) and Aortic Valve Calcification
N/A

Open Jobs (1405)

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

California - San Francisco, US
Medical Affairs
23h ago

Sr Maintenance Technician (Shifts)

Netherlands - Breda
Manufacturing
23h ago

Lead Automation Technician / Engineer

Netherlands - Breda
Engineering
23h ago

Maintenance Team Lead (Shifts)

Netherlands - Breda
Manufacturing
23h ago

Manager Maintenance

Netherlands - Breda
Manufacturing
23h ago

Senior Oncology Specialist - TOPAZ - Allentown, PA

Pennsylvania - Allentown, US
Commercial
Yesterday
$159K - $177K/yr

Clinical Scientist Associate Director - Late Development, Oncology

Portugal - Lisbon
Clinical Operations
Yesterday

Director Execution Excellence

California - Thousand Oaks, US
IT
Yesterday

Senior Associate Business Analyst

Portugal - Lisbon
Yesterday

Warehouse Technician (Fixed Term Contract - Shift)

Ireland - Dun Laoghaire
Supply Chain
Yesterday

Praktikant (m/w/d) Marketing Onkologie

Germany - Munich
Commercial
Yesterday

Medical Science Liaison, NMOSD & gMG-Rare Disease - W. NC, SC

North Carolina - Charlotte, US
Medical Affairs
Yesterday

Medical Science Liaison, NMOSD & gMG-Rare Disease - ME, NH, VT, N. MA

Massachusetts - Boston, US
Medical Affairs
Yesterday

Medical Science Liaison, IgG4 - Rare Disease - CO/NM/OK

Colorado - Denver, US
Medical Affairs
Yesterday

Medical Science Liaison, IgG4 - Rare Disease - Southern California

California - Los Angeles, US
Medical Affairs
Yesterday

Medical Science Liaison, IgG4 - Rare Disease - South Carolina/East Georgia

South Carolina - Columbia, US
Medical Affairs
Yesterday

Medical Science Liaison, IgG4 - Rare Disease - North Texas/North Louisiana

Texas - Dallas, US
Medical Affairs
Yesterday

Associate Director, Commercial Data Science

California - Thousand Oaks, US
Data Science & AI
Yesterday

Engineer - Process Development

Ohio - New Albany, US
Manufacturing
Yesterday

Sr. Associate Technical Engineer- Day Shift 12 Hour (6:00am-6:00pm)

Ohio - New Albany, US
Engineering
Yesterday

Bioprocess Technician

Ireland - Dublin
Manufacturing
Yesterday

Medical Science Liaison, IgG4 - Rare Disease - Mississippi/Alabama/FL Panhandle

Alabama - Birmingham, US
Medical Affairs
Yesterday

Manufacturing Process Technician- 12 Hour Day Shift 6am-6pm

Ohio - New Albany, US
Manufacturing
Yesterday

Medical Science Liaison, IgG4 - Rare Disease - Michigan

Michigan - Detroit, US
Medical Affairs
Yesterday

Medical Value and Access Liaison -Central US

North Carolina - Charlotte, US
Medical Affairs
Yesterday
View all 1405 open positions →
Interview Prep Quick Facts
Founded: 1980
Portfolio: 41 approved products, 162 clinical trials
Top TAs: Oncology, Immunology, Hematology
H-1B (2023): 3 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 1405 active jobs
Portfolio Health
Launch2 (5%)
Growth5 (12%)
Peak16 (39%)
LOE Approaching18 (44%)
41 total products
Therapeutic Area Focus
Oncology
10 marketed666 pipeline
Immunology
5 marketed193 pipeline
Hematology
4 marketed82 pipeline
Nephrology
3 marketed83 pipeline
Metabolic Diseases
1 marketed75 pipeline
Endocrinology
1 marketed51 pipeline
Neurology
2 marketed44 pipeline
Cardiovascular
3 marketed37 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$28.2B7%
R&D Spend
$4.8B(17%)8%
Net Income
$6.7B
Cash
$12.0B
Source: SEC 10-K Filing

Hiring Trend

Actively Hiring
1405
Open Roles
+1433
Added
-68
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
3
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub